Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE
Insilico Medicine has nominated ISM0387, the UAE's first preclinical candidate, using its AI-powered drug discovery platform. The candidate is an MTA-cooperative PRMT5 inhibitor with improved activity and selectivity.
Insilico Medicine has announced the nomination of ISM0387, the UAE's first preclinical candidate, jointly with the Emirates Drug Establishment (EDE). The candidate was discovered locally using Insilico's proprietary Pharma.AI platform. ISM0387 is an MTA-cooperative PRMT5 inhibitor with AI-powered novel structure, showing improved activity and selectivity. Insilico's team screened 90 AI-powered novel candidates, completing the lead discovery phase in six months. The nomination marks Insilico's 30th AI-supported preclinical candidate and signals a major step forward in the UAE's sovereign biotechnological capabilities. The achievement was supported by local partners, including Abu Dhabi Investment Office and the Department of Health Abu Dhabi.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.